Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Multicenter, Randomized, Double-blinded, Placebo-controlled Phase III Trial to Evaluate the Efficacy, Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older

Authors not listed

Jiangsu Rec-Biotechnology Co., Ltd. · 2022

Dysbiosis Human Randomized controlled trial

Abstract

This is a multicenter designed Phase III clinical trial. About 10000 participants plan to be enrolled.The objectives of this study are to evaluate the efficacy, safety and immunogenicity of the recombinant two-component COVID-19 vaccine (CHO cell) in adults

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-11-06 MST

Cite this

APA

Anonymous. (2022). A Multicenter, Randomized, Double-blinded, Placebo-controlled Phase III Trial to Evaluate the Efficacy, Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older. <em>Jiangsu Rec-Biotechnology Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT05398848

Vancouver

Anonymous. A Multicenter, Randomized, Double-blinded, Placebo-controlled Phase III Trial to Evaluate the Efficacy, Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older. Jiangsu Rec-Biotechnology Co., Ltd.. 2022.

BibTeX

@misc{anon2022AMulti, title = {A Multicenter, Randomized, Double-blinded, Placebo-controlled Phase III Trial to Evaluate the Efficacy, Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older}, author = {Anonymous}, journal = {Jiangsu Rec-Biotechnology Co., Ltd.}, year = {2022}, }